NEW YORK, July 1 (newratings.com) - Analysts at Citigroup initiate coverage of Halliburton Company (ticker: HAL) with a "buy" rating. The target price is set to $63. [more]
NEW YORK, July 1 (newratings.com) - Analysts at Caris & Company initiate coverage of Par Pharmaceutical Companies Inc (ticker: PRX) with an "average" rating. The target price is set to $16. [more]
NEW YORK, July 1 (newratings.com) - Analysts at Robert W Baird initiate coverage of MedAssets Inc (ticker: MDAS) with a "neutral" rating. The target price is set to $18. [more]
NEW YORK, July 1 (newratings.com) - Analysts at Feltl & Co initiate coverage of Ramtron International Corporation (ticker: RMTR) with a "buy" rating. The target price is set to $6. [more]
NEW YORK, July 1 (newratings.com) - Analysts at Citigroup initiate coverage of National Oilwell Varco Inc (ticker: NOV) with a "buy" rating. The target price is set to $92. [more]
NEW YORK, July 1 (newratings.com) - Analysts at Needham & Co initiate coverage of Optimer Pharmaceuticals Inc (ticker: OPTR) with a "buy" rating. The target price is set to $13. [more]
NEW YORK, July 1 (newratings.com) - Analysts at Citigroup initiate coverage of Schlumberger Ltd (ticker: SLB) with a "buy" rating. The target price is set to $120. [more]
NEW YORK, July 1 (newratings.com) - Analysts at Citigroup initiate coverage of Smith International Inc (ticker: SII) with a "hold" rating. The target price is set to $85. [more]
NEW YORK, July 1 (newratings.com) - Analysts at Citigroup initiate coverage of Baker Hughes Inc (ticker: BHI) with a "hold" rating. The target price is set to $90. [more]
NEW YORK, July 1 (newratings.com) - Analysts at Jefferies & Co initiate coverage of T 3 Energy Services Inc (ticker: TTES) with a "buy" rating. The target price is set to $95. [more]
NEW YORK, July 1 (newratings.com) - Analysts at Kaufman Bros initiate coverage of Terremark Worldwide Inc (ticker: TMRK) with a "buy" rating. The target price is set to $8. [more]
NEW YORK, July 1 (newratings.com) - Analysts at Needham & Co initiate coverage of Cubist Pharmaceuticals Inc (ticker: CBST) with a "buy" rating. The target price is set to $24. [more]
